http://www.rxpgnews.com/ Medical News and Information Thu, 21 Aug 2008 02:00:28 PST en-us http://www.rxpgnews.com/anticancerdrugs/Anti-angiogenics_a_novel_class_of_drugs_against_so_4648_4648.shtml Anti Cancer Drugs Researchers at the University of Minnesota have developed novel anti-cancer drugs to treat solid tumors. These "small molecules" belong to a class of pharmaceutical agents called anti-angiogenics. The new compounds are a refined form of drugs that effectively reduce blood flow to the tumor, thereby inhibiting tumor growth. Thu, 06 Jul 2006 03:04:00 PST http://www.rxpgnews.com/anticancerdrugs/Anti-angiogenics_a_novel_class_of_drugs_against_so_4648_4648.shtml http://www.rxpgnews.com/rituximab/Rituximab_effective_in_treating_chronic_graft-vers_3771_3771.shtml Rituximab A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants. Fri, 24 Mar 2006 19:15:00 PST http://www.rxpgnews.com/rituximab/Rituximab_effective_in_treating_chronic_graft-vers_3771_3771.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_Anti-Viral_Hepatitis_C_Clinical_Progra_3135_3135.shtml Tarvacin Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus infection (HCV). Wed, 18 Jan 2006 18:01:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_Anti-Viral_Hepatitis_C_Clinical_Progra_3135_3135.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_effective_in_controlling_Pancreatic_Cance_3110_3110.shtml Tarvacin Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced preclinical results showing that 3G4, the mouse equivalent of Tarvacin(TM) Anti-Cancer, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with the standard-of-care chemotherapy gemcitabine. Wed, 11 Jan 2006 19:21:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_effective_in_controlling_Pancreatic_Cance_3110_3110.shtml http://www.rxpgnews.com/rituximab/Rituximab_maintenance_therapy_dramatically_improve_2998_2998.shtml Rituximab Two years of maintenance therapy with MabThera (rituximab) dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin’s Lymphoma (NHL). The trial showed that the risk of death is halved for patients who receive MabThera maintenance therapy, compared to those who receive no maintenance treatment, irrespective of their initial therapy. “We are conscious that these results open a new era in the management of indolent NHL“, said William M. Burns, CEO of the Pharmaceuticals Division at Roche. “Maintenance therapy with MabThera showed unprecedented survival benefits in a serious cancer disease which is currently considered incurable.” Tue, 13 Dec 2005 15:36:00 PST http://www.rxpgnews.com/rituximab/Rituximab_maintenance_therapy_dramatically_improve_2998_2998.shtml http://www.rxpgnews.com/tarvacin/Peregrine_Pharmaceuticals_Evaluating_Therapeutic_O_2702_2702.shtml Tarvacin Tue, 25 Oct 2005 05:11:00 PST http://www.rxpgnews.com/tarvacin/Peregrine_Pharmaceuticals_Evaluating_Therapeutic_O_2702_2702.shtml http://www.rxpgnews.com/anticancerdrugs/Balancing_Chk1_activity_might_produce_less_toxic_c_2225_2225.shtml Anti Cancer Drugs A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs. The study is expected to help academic researchers and biotechnology and pharmaceutical companies design drugs that combat cancer using this checkpoint protein, but with fewer side effects. Sun, 04 Sep 2005 08:33:00 PST http://www.rxpgnews.com/anticancerdrugs/Balancing_Chk1_activity_might_produce_less_toxic_c_2225_2225.shtml http://www.rxpgnews.com/rituximab/Rituximab_to_be_Considered_for_Front-Line_Treatmen_2094_2094.shtml Rituximab Genentech, Inc. , Biogen Idec, Inc. and Roche (SWX Zurich) today announced that the companies completed the filing of a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication for Rituxan(R) (Rituximab), in previously untreated (front-line) patients with intermediate grade or aggressive, CD-20-positive, B-cell, non-Hodgkin's lymphoma (NHL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens. Thu, 18 Aug 2005 11:45:00 PST http://www.rxpgnews.com/rituximab/Rituximab_to_be_Considered_for_Front-Line_Treatmen_2094_2094.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_starts_with_Phase_I_study_against_Hepa_2010_2010.shtml Tarvacin Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), announced today the initiation of a phase I anti-viral study of Tarvacin(TM), the Company's first Anti-Phospholipid Therapy candidate. The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy. Mon, 08 Aug 2005 17:40:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_starts_with_Phase_I_study_against_Hepa_2010_2010.shtml http://www.rxpgnews.com/tarvacin/New_data_support_broad_anti-viral_potential_of_Tar_1979_1979.shtml Tarvacin The data presented at BIO 2005 showed that Tarvacin(TM) binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin(TM) provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections. Mon, 01 Aug 2005 00:00:00 PST http://www.rxpgnews.com/tarvacin/New_data_support_broad_anti-viral_potential_of_Tar_1979_1979.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_also_useful_in_imaging_solid_tumors_1978_1978.shtml Tarvacin Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors. Sun, 31 Jul 2005 23:13:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_also_useful_in_imaging_solid_tumors_1978_1978.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_to_be_evaluated_for_the_treatment_of_L_1977_1977.shtml Tarvacin Peregrine Pharmaceuticals Inc. has announced that it has signed a Cooperative Research and Development Agreement (CRADA) for Material Transfer with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of Tarvacin(TM) to treat hemorrhagic diseases resulting from Ebola and Marburg viral infections. Sun, 31 Jul 2005 23:02:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_to_be_evaluated_for_the_treatment_of_L_1977_1977.shtml http://www.rxpgnews.com/rituximab/DANCER_Study_shows_RA_drug_rituximab_is_safe_and_w_1671_1671.shtml Rituximab In the biggest study of its kind, researchers have shown that the drug rituximab, used to treat rheumatoid arthritis (RA) is safe and effective. The results were presented for the first time today (Thursday 9 June), at the Annual European Congress of Rheumatology, EULAR 2005, in Vienna. Thu, 09 Jun 2005 13:26:00 PST http://www.rxpgnews.com/rituximab/DANCER_Study_shows_RA_drug_rituximab_is_safe_and_w_1671_1671.shtml http://www.rxpgnews.com/rituximab/Rituximab_may_also_benefit_people_with_lupus_1672_1672.shtml Rituximab A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy. Thu, 09 Jun 2005 13:26:00 PST http://www.rxpgnews.com/rituximab/Rituximab_may_also_benefit_people_with_lupus_1672_1672.shtml http://www.rxpgnews.com/anticancerdrugs/PXD101_A_Small_Molecule_HDAC_Inhibitor_for_Advance_1482_1482.shtml Anti Cancer Drugs CuraGen Corporation (Nasdaq: CRGN - News) and TopoTarget A/S announced that preliminary Phase I data on PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of advanced solid tumors were presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. Tue, 17 May 2005 08:43:00 PST http://www.rxpgnews.com/anticancerdrugs/PXD101_A_Small_Molecule_HDAC_Inhibitor_for_Advance_1482_1482.shtml http://www.rxpgnews.com/anticancerdrugs/FDA_Permits_Phase_IIb_Kidney_Transplant_Trial_1457_1457.shtml Anti Cancer Drugs Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. Fri, 13 May 2005 17:45:00 PST http://www.rxpgnews.com/anticancerdrugs/FDA_Permits_Phase_IIb_Kidney_Transplant_Trial_1457_1457.shtml http://www.rxpgnews.com/anticancerdrugs/TNFerade_TM_to_be_Studied_for_Locally_Advanced_Pan_1432_1432.shtml Anti Cancer Drugs Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GenVec, Inc. (NASDAQ: GNVC) has selected Phase Forward's InForm(TM) electronic data capture (EDC) solution to manage a randomized, controlled Phase II clinical trial of its investigational oncology drug, TNFerade(TM). Tue, 10 May 2005 20:40:00 PST http://www.rxpgnews.com/anticancerdrugs/TNFerade_TM_to_be_Studied_for_Locally_Advanced_Pan_1432_1432.shtml http://www.rxpgnews.com/anticancerdrugs/Motexafin_Gadolinium_Works_by_Disrupting_Key_Metab_1318_1318.shtml Anti Cancer Drugs The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California. Sun, 01 May 2005 20:58:00 PST http://www.rxpgnews.com/anticancerdrugs/Motexafin_Gadolinium_Works_by_Disrupting_Key_Metab_1318_1318.shtml